Eli Lilly's investment in AI-designed therapeutics could revolutionize treatment options for conditions lacking effective injectable solutions.
The post Eli Lilly invests $40M in Absci for AI-designed injectable antibody ABS-201 appeared first on Crypto Briefing.
The post Top 3 Healthcare Stocks to Buy and Hold in 2026 appeared on BitcoinEthereumNews.com.
Key Takeaways Eli Lilly dominates the weight-loss and diabetes medication sector with Zepbound and Mounjaro, supported by robust research and development Abbott Laboratories offers balanced exposure through medical devices, laboratory diagnostics, and nutritional products Johnson & Johnson has streamlined operations around pharmaceuticals and medical technology following its consumer division spinoff These companies capitalize on demographic shifts and increasing healthcare consumption worldwide Market participants are shifting capital from overvalued tech equities toward stable healthcare investments in 2026 As 2026 unfolds, healthcare equities are capturing significant investor attention amid a broader rotation away from elevated technology valuations. Three pharmaceutical and medical device leaders stand out: Eli Lilly, Abbott Laboratories, and Johnson & Johnson. Eli Lilly Eli Lilly has eme
AI-driven drug discovery's rapid progression to human trials could revolutionize biotech timelines, potentially accelerating medical advancements.
The post Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery appeared first on Crypto Briefing.
The post CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo appeared on BitcoinEthereumNews.com.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images CVS Health on Thursday said it will restore coverage of Eli Lilly‘s blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans – a win for the drugmaker and certain patients who will be able to access more treatment options. CVS will add Zepbound coverage on Oct. 1, and start covering Lilly’s newly approved Foundayo pill on June 1. The move will boost Lilly’s efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing in major plans. It comes a year after CVS struck a deal with Novo Nordisk to make its drug Wegovy the preferred obesity treatment on its standard plans, while dro
The post Eli Lilly’s $4 Billion Vaccine Bet appeared on BitcoinEthereumNews.com.
In this week’s edition of InnovationRx, we look at the spreading Ebola epidemic, the Midas list health investors, Lilly’s trio of vaccine deals, and more. To get it in your inbox, subscribe here. Health workers leaving the isolation area at Congo’s General Referral Hospital during the Ebola outbreak response. Getty Images In less than two weeks since the Africa Center for Disease Control confirmed an Ebola outbreak in the Democratic Republic of the Congo, more than 220 people have been killed by the disease. The total number of people infected has now topped 1,000, and the disease has spread to neighboring Uganda. On Monday, the head of the World Health Organization, Tedros Adhanom Ghebreyesus, said the disease was spreading faster than response efforts, leaving public health workers “playing catch-up.” The outbreak could surpass the 2018-2020 one, which was the biggest on record and caused more than 2,290
Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus on cancer treatment, in a deal valued at up to $7 billion in cash.
